BioCatalystWatch
IMCRWorkspace / IMCR / OverviewCompany library
Immunocore Holdings plc logo

Immunocore Holdings plc

Immunocore Holdings plc (IMCR)

Website

Price
Market cap
Next catalystExpected 2H 2026IMC-P115C · Phase 1 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

gp100 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

IMC-I109V

HBV envelope antigen (HBsAg) × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

IMC-R117C

PIWIL1–HLA-A*02:01 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

IMC-U120AI

CD1a × PD-1

Upcoming / outlook

HIV Gag–HLA-A*02:01 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

IMC-P115C

PRAME–HLA-A*02 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

brenetafusp plus nivolumab — PRISM-MEL-301

CD3 / PRAME–HLA-A*02:01

PreINDP1P2P3FilingApproved
Upcoming / outlook

CD3 / PRAME–HLA-A*02:01

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

CD3 / PRAME–HLA-A*02:01

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

CD3 / PRAME–HLA-A*02:01

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

IMC-I109V

HBV envelope antigen (HBsAg) × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

IMC-P115C

PRAME–HLA-A*02 × CD3

PreINDP1P2P3FilingApproved
Upcoming / outlook

CD3 / PRAME–HLA-A*02:01

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

CD3 / PRAME–HLA-A*02:01

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

CD3 / PRAME–HLA-A*02:01

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

IMC-U120AI

CD1a × PD-1

Upcoming / outlook

Other pipelines

IMC-I109V

HBV envelope antigen (HBsAg) × CD3

IMC-S118AI

PPI–HLA-A*02 × PD-1

PreINDP1P2P3FilingApproved

PRAME × CD3; gp100 × CD3

Upcoming / outlook

Approved / commercial

gp100 × CD3

Approved

PreINDP1P2P3FilingApproved
Upcoming / outlook

History / paused

MAGE-A4–HLA-A*02:01 × CD3

PreINDP1P2P3FilingApproved

MAGE-A4–HLA-A*02:01 × CD3

PreINDP1P2P3FilingApproved
GSK-01

NY-ESO

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Operating
Investing
Financing

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

IMCR PR & News

PR & News

IMCR SEC archive